Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Anti-CEACAM6 AFAIKL2 Antibody Fragment/Jack Bean Urease Immunoconjugate L-DOS47

Known as: L-DOS47 
A lyophilized formulation of DOS47, an immunoconjugate composed of AFAIKL2, a recombinant camelid single-domain antibody which recognizes… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Development and Characterization of a Camelid Single Domain Antibody–Urease Conjugate That Targets Vascular Endothelial Growth Factor Receptor 2
Angiogenesis is the process of new blood vessel formation and is essential for a tumor to grow beyond a certain size. Tumors… Expand
  • figure 2
2015
2015
Production and characterization of a camelid single domain antibody-urease enzyme conjugate for the treatment of cancer.
A novel immunoconjugate (L-DOS47) was developed and characterized as a therapeutic agent for tumors expressing CEACAM6. The… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
2013
2013
Abstract 2851: Development of an alkalizing antibody-enzyme conjugate for NSCLC treatment that is in Phase I clinical testing.
Many solid human tumors generate an acidic and hypoxic microenvironment as a result of altered metabolic pathways and aberrant… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE